SCHEMBL30786165

SCHEMBL30786165

C=Cc1ccc(OCCN2CCOCC2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 1/20 0.56
ALDH1A1 P00352 3/20 0.53
NPC1 O15118 2/20 0.53
KDM4E B2RXH2 2/20 0.53
RAB9A P51151 1/20 0.53
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CYP1A2 P05177 2/20 0.50
HRH3 Q9Y5N1 2/20 0.50
MAPK1 P28482 2/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
CHRM2 P08172 1/20 0.50
CHRM1 P11229 1/20 0.50
HTR2A P28223 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30786066 0.87 PSMB1 (0.57) LTA4HHRH3
SCHEMBL19632873 0.81 NPC1 (0.61) LTA4HALDH1A1NPC1KDM4ERAB9A
SCHEMBL21119254 0.79 LTA4H (0.64) LTA4HALDH1A1NPC1KDM4ERAB9A
SCHEMBL30586324 0.78 PRKAB2 (0.61) LTA4HALDH1A1NPC1KDM4ERAB9A
SCHEMBL16535859 0.78 TSHR (0.61) LTA4HALDH1A1NPC1KDM4ERAB9A
SCHEMBL20037920 0.78 NPC1 (0.60) LTA4HALDH1A1NPC1KDM4ERAB9A
SCHEMBL4465091 0.78 PRKAB2 (0.61) LTA4HALDH1A1NPC1KDM4ERAB9A
SCHEMBL5199779 0.78 ALDH1A1 (0.65) LTA4HALDH1A1NPC1KDM4ERAB9A
SCHEMBL29495619 0.78 ALDH1A1 (0.65) LTA4HALDH1A1NPC1KDM4ERAB9A
SCHEMBL20037918 0.78 ALDH1A1 (0.57) LTA4HALDH1A1NPC1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
WO-2025082316-A1 OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州必扬医药科技有限公司 2025-04-24 WO disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 LTA4H 2626/4885ALDH1A1 3745/4885NPC1 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.